Psilocybin’s effects may extend beyond the trip itself
A single dose of psilocybin may leave the brain changed for weeks, according to new research from UC San Francisco and Imperial College London. In a study of healthy volunteers with no prior psychedelic use, researchers found evidence that the compound triggered short-term changes in brain activity and likely anatomical changes that persisted for as long as a month after the experience.
The study, published in Nature Communications, adds to a growing body of work examining why psychedelic compounds have shown promise in treating depression, anxiety, and addiction. Rather than focusing only on the immediate subjective experience, the researchers tried to connect what was happening in the brain during the drug’s peak effects with how participants felt in the days and weeks that followed.
The central concept in the study is “entropy,” described here as the diversity or complexity of neural activity in the brain. The researchers found that higher doses of psilocybin increased entropy in the minutes and hours after participants took the drug. That mattered because the degree of this change was linked to how much insight or emotional self-awareness participants reported the next day. Those reported insights, in turn, forecast improvements in well-being one month later.
Why the researchers think insight matters
The work supports an idea that has become increasingly important in psychedelic science: the therapeutic value may not come from the chemical alone, but from the altered mental state it produces. Senior author Robin Carhart-Harris said the findings suggest that the psychedelic experience itself, and its brain correlates, are a key part of how psychedelic therapy may work.
That conclusion is notable because it pushes back against a simpler pharmaceutical model in which a drug’s benefits are assumed to be separable from the experience of taking it. In this study, the chain the researchers highlight runs from brain entropy to psychological insight to improved well-being. The implication is that the acute experience may be doing clinically relevant work.
The study was carried out in 28 healthy volunteers, a design choice that gave the team more freedom to use multiple monitoring techniques without the complications of an active psychiatric disorder. Participants underwent a range of brain measurements before dosing, during the peak experience, and again one month later. In the first part of the experiment, they received a 1 milligram dose that researchers treated as a placebo condition while recording brain activity with electroencephalography, or EEG.
Although the source summary only partially details the full protocol, it makes clear that the study used multiple imaging and measurement methods and that some observations were made during the peak psychedelic state. That combination is important because it lets researchers compare the immediate disruption of ordinary brain activity with the longer-lasting changes seen later.
